olcegepant

structure in first source

Also Known As:

(R-(R*,S*))-N-(2-((5-amino-1-((4-(4-pyridinyl)-1-piperazinyl)carbonyl)pentyl)amino)-1-((3,5-dibromo-4-hydroxyphenyl)methyl)-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)quinazolinyl)-1-piperidinecarboxamide; (R-(R,(R*,S*))-N-(2-(5-amino-1-((4-(4-pyridinyl)-1-piperazinyl)carbonyl) pentyl)amino)-1-((3,5-dibromo-4-hydroxyphenyl)methyl)-2-oxoethyl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-,1-Piperidinecarboxamide; BIBN 4096BS; BIBN4096BS

Networked: 86 relevant articles (22 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - olcegepant: 86
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - olcegepant: 86

Experts

1.	Olesen, Jes: 9 articles (01/2021 - 11/2004)
2.	Hay, Debbie L: 4 articles (01/2018 - 01/2005)
3.	Doods, Henri: 4 articles (05/2013 - 08/2003)
4.	Edvinsson, Lars: 4 articles (02/2008 - 01/2002)
5.	Christensen, Sarah L: 3 articles (01/2021 - 12/2019)
6.	Goadsby, Peter J: 3 articles (01/2020 - 02/2012)
7.	Petersen, Steffen: 3 articles (12/2019 - 12/2015)
8.	Jansen-Olesen, Inger: 3 articles (01/2018 - 02/2014)
9.	Russo, Andrew F: 3 articles (01/2018 - 08/2007)
10.	Martelletti, Paolo: 3 articles (06/2012 - 09/2008)

Related Diseases

1.	Migraine Disorders (Migraine) 08/01/2004 - "CGRP has been implicated in migraine, and the nonpeptide CGRP antagonist BIBN4096BS has been shown to be effective in clinical trials in migraine. " 06/10/2005 - "The role of CGRP in migraine is further supported by recently released data showing that the CGRP-antagonist BIBN4096BS is clinically effective for the treatment of migraine headaches. " 02/01/2005 - "BIBN4096BS is a CGRP-antagonist effective in the treatment of migraine. " 01/01/2005 - "In vivo, clinical studies have shown that BIBN4096BS is likely to be useful in the treatment of migraine. " 02/01/2014 - "These findings also predict that pre-treatment with olcegepant may be a better option than post-treatment to study its inhibitory effect in GTN migraine models."
2.	Pain (Aches) 11/09/2022 - "Moreover, olcegepant treatment significantly elevated the threshold for facial heat pain at 72 h after CSD. " 04/01/2022 - "Co-administration of aprepitant and olcegepant more significantly alleviated pain behaviors than administration of single agents or vehicle, increasing the mechanical threshold and improving the response latency. " 10/01/2014 - "Spinal administration of BIBN4096BS did not modify the neuronal activity in the CFA model which suggests that peripheral blockade of CGRP receptors by BIBN4096BS significantly alleviates inflammatory pain. " 05/01/2013 - "Peripheral blockade of CGRP receptors by BIBN4096BS significantly alleviates inflammatory pain." 05/01/2013 - "The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats."
3.	Hyperalgesia 09/30/2022 - "Olcegepant may alleviate hyperalgesia of the hind paw and periorbital area by attenuating brain activation in CMMs." 09/30/2022 - "In two CMMs, acute and basal mechanical hyperalgesia was observed, and olcegepant alleviated mechanical hyperalgesia. " 09/30/2022 - "Olcegepant was administered to explore its effect on mechanical hyperalgesia and brain region activation. " 03/08/2022 - "BIBN4096BS treatment and PKC inhibition alleviated mechanical allodynia, thermal hyperalgesia and vestibular dysfunction in CM rats. " 01/01/2020 - "Persistent exposure of mice to the 5-HT1F agonist LY344864, but not olcegepant produced a significant reduction in hind paw and orofacial mechanical withdrawal thresholds as a surrogate readout of allodynia. "
4.	Headache (Headaches) 03/01/2005 - "These results show that BIBN4096BS effectively prevents CGRP-induced headache and extracerebral vasodilatation but does not significantly affect the induced cerebral hemodynamic changes." 03/01/2005 - "Of the 10 volunteers, 6 had a CGRP-induced headache during the in-hospital phase after placebo pretreatment but none after BIBN4096BS (P = .031). " 03/01/2005 - "We investigated the ability of BIBN4096BS to inhibit human alphaCGRP (h-alphaCGRP)-induced headache and cerebral hemodynamic changes in healthy volunteers. " 08/01/2007 - "In a phase II clinical trial, olcegepant reduced the severity of headache in 60% of migraine sufferers and met secondary endpoints including headache-free rate and rate of sustained response. " 12/01/2009 - "Intravenous olcegepant 2.5 mg resulted in 66% headache relief after 2 h, whereas subcutaneous sumatriptan resulted in 81-92% headache relief after 2 h. "
5.	Sepsis (Septicemia) 01/01/2022 - "CGRP receptor antagonism with olcegepant was not beneficial in this porcine model of polymicrobial sepsis, which closely mimics human sepsis." 01/01/2022 - "The CGRP receptor antagonist olcegepant improves survival in murine sepsis. "

Related Drugs and Biologics

1.	Calcitonin Gene-Related Peptide Receptor Antagonists
2.	telcagepant
3.	olcegepant
4.	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
5.	Calcitonin Gene-Related Peptide
6.	Peptides (Polypeptides)
7.	1- (N(2)- (3,4- dibromo- N- ((4- (3,4- dihydro- 2(1H)- oxoquinazolin- 3- yl)- 1- piperidinyl)carbonyl)tyrosyl)lysyl)- 4- (4- pyridinyl)piperazine
8.	2- (8- (3,5- difluorophenyl)- 10- oxo- 6,9- diazaspiro(4.5)dec- 9- yl)- N- (2'- oxo- 1,1',2',3- tetrahydrospiro(indene- 2,3'- pyrrolo(2,3- b)pyridin)- 5- yl)acetamide
9.	ubrogepant
10.	Naproxen (Naprosyn)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Therapeutics
3.	Microspheres (Microsphere)
4.	Ligation
5.	Intravenous Infusions